Genetix Biotherapeutics
Genetix Biotherapeutics develops one‑time, autologous stem‑cell gene therapies that insert functional copies of defective genes into a patient’s own blood stem cells, offering potential cures for sickle cell disease, β‑thalassemia, and cerebral adrenoleukodystrophy. The therapies are FDA‑approved, manufactured under GMP conditions, and supported by long‑term safety monitoring and patient support services that assist with insurance, logistics, and care coordination.
- Biotechnology
Funding
Funding not disclosed
Founders
Product
Problem
Patients with rare genetic blood disorders such as sickle cell disease, β‑thalassemia, and cerebral adrenoleukodystrophy have limited treatment options that only manage symptoms and require lifelong interventions, leading to frequent hospitalizations, organ damage, and reduced life expectancy.
Solution
Genetix Biotherapeutics (formerly bluebird bio) develops one‑time, autologous stem‑cell gene therapies that insert functional copies of the defective gene into a patient’s own blood stem cells. The modified cells are infused back into the patient, restoring normal gene function and providing a potential cure for the underlying disease. Each therapy is manufactured under GMP conditions, has received FDA approval, and is supported by long‑term safety monitoring programs that follow patients for up to 15 years. The company also offers a patient services program that assists families with insurance navigation, treatment center coordination, and ongoing support throughout the therapy journey.
Target Audience
Primary customers are healthcare systems, specialty treatment centers, and insurers that provide care for patients with rare, genetic blood disorders, as well as the patients and families seeking curative therapy.
Features
- Autologous hematopoietic stem‑cell collection, ex vivo gene addition, and reinfusion as a single administration
- FDA‑approved, first‑in‑class gene therapies for sickle cell disease, β‑thalassemia, and cerebral adrenoleukodystrophy
- Integrated long‑term follow‑up studies tracking safety and efficacy for up to 15 years post‑treatment
- Patient support services covering insurance, logistics, and personalized care coordination
- Manufacturing platform based on viral vector delivery of functional gene copies to ensure consistent product quality